Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | Sb |
| Molecular Weight | 121.76 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Sb]
InChI
InChIKey=OUULRIDHGPHMNQ-UHFFFAOYSA-N
InChI=1S/Sb.3H
Antimony (Sb) is a toxic metalloid that occurs widely at trace concentrations in soil, aquatic systems, and the atmosphere. Antimony is not an abundant element but is found in small quantities in over 100 mineral species. It is most often found as antimony(III) sulfide. Antimony is used in the electronics industry to make some semiconductor devices, such as infrared detectors and diodes. It is alloyed with lead or other metals to improve their hardness and strength. A lead-antimony alloy is used in batteries. Other uses of antimony alloys include type metal (in printing presses), bullets and cable sheathing. Antimony has been in medical use against microbes and parasites as well. Antimony-based drugs have been prescribed against leishmaniasis since the parasitic transmission of the tropical disease was understood in the beginning of the 20th century. As a therapeutic, antimony has been mostly used for the treatment of leishmaniasis and schistosomiasis. The major toxic side-effects of antimonials as a result of therapy are cardiotoxicity (~9% of patients) and pancreatitis, which is seen commonly in HIV and visceral leishmaniasis co-infections.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML. | 2015-09-15 |
|
| Monitoring of intracellular nitric oxide in leishmaniasis: its applicability in patients with visceral leishmaniasis. | 2011-01 |
|
| [An adult case of visceral leishmaniasis in a province of Black-Sea region, Turkey]. | 2010-10 |
|
| A case with two unusual findings: cutaneous leishmaniasis presenting as panniculitis and pericarditis after antimony therapy. | 2010-03 |
|
| A case of visceral leishmaniasis in Oltenia region (Romania). | 2010 |
|
| Cutaneous leishmaniasis with boggy induration and simultaneous mucosal disease. | 2009-01 |
|
| Characterization and distribution of the selected metals in the scalp hair of cancer patients in comparison with normal donors. | 2007-09 |
|
| Classification of heavy-metal toxicity by human DNA microarray analysis. | 2007-05-15 |
|
| Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9. | 2004-09-24 |
|
| Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam. | 2004-09-03 |
|
| Functional identification of ion binding sites at the internal end of the pore in Shaker K+ channels. | 2003-05-15 |
|
| In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate. | 2002-05-02 |
|
| Novel bicistronic retroviral vector expressing gamma-glutamylcysteine synthetase and the multidrug resistance protein 1 (MRP1) protects cells from MRP1-effluxed drugs and alkylating agents. | 2001-09-20 |
|
| Cutaneous leishmaniasis in an Italian woman: case report. | 2001-06 |
|
| Leishmaniasis in Sudan. Mucosal leishmaniasis. | 2001-04 |
|
| Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation. | 2000-11 |
|
| Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. | 2000-11 |
|
| [Hematologic characteristics of leishmaniasis]. | 2000-08-23 |
|
| [American cutaneous leishmaniasis in the Federal District]. | 2000-07-06 |
|
| Mucosal leishmaniasis: quantitative nasal cytology as a marker of disease activity and indicator of healing. | 2000-01 |
|
| Marked elevation of myocardial trace elements in idiopathic dilated cardiomyopathy compared with secondary cardiac dysfunction. | 1999-05 |
|
| Leishmaniasis of glans penis. | 1998-05 |
|
| Efficacy and Tolerability of Liposomal Amphotericin B (Ambisome) in the Treatment of Visceral Leishmaniasis in Brazil. | 1997-10 |
|
| Treatment of New World cutaneous and mucosal leishmaniases. | 1996-09-01 |
|
| [Clinical and pathogenetic features of exposure of workers to antimonate ore]. | 1996 |
|
| Interleukin 6 during active visceral leishmaniasis and after treatment. | 1995-10 |
|
| Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. | 1994-11-15 |
|
| Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral Leishmaniasis. | 1994 |
|
| [Interferon gamma as an immunological strategy for the treatment of human leishmaniasis]. | 1994 |
|
| [Visceral leishmaniasis and multiple organ failure]. | 1993-12 |
|
| Response to chemotherapy in experimental visceral leishmaniasis: T cell-dependent but interferon-gamma- and interleukin-2-independent. | 1991-03 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
3349 (Number of products:23)
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
||
|
CFR |
21 CFR 862.3110
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
||
|
NCI_THESAURUS |
C1940
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID5023879
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
PRIMARY | |||
|
30304
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
PRIMARY | |||
|
30513
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
PRIMARY | |||
|
m1953
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB13110
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
PRIMARY | |||
|
D000965
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
PRIMARY | |||
|
1311407
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
PRIMARY | RxNorm | ||
|
5354495
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
PRIMARY | |||
|
508
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
PRIMARY | |||
|
100000077405
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
PRIMARY | |||
|
9IT35J3UV3
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
PRIMARY | |||
|
9IT35J3UV3
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
PRIMARY | |||
|
C95187
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
PRIMARY | |||
|
231-146-5
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
PRIMARY | |||
|
SUB12914MIG
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
PRIMARY | |||
|
7440-36-0
Created by
admin on Mon Mar 31 18:43:49 GMT 2025 , Edited by admin on Mon Mar 31 18:43:49 GMT 2025
|
PRIMARY |
ACTIVE MOIETY